This study is a triple-blind clinical trial study. The trial was registered prior to patient enrollment at IRCT (IRCT2014060918020N1). The study was conducted from September 2016 to December 2018. In September 2016, this study was approved by the Vice-chancellor for Research of Iran University of Medical Sciences, and the ethics code was obtained from the relevant Ethics Committee (Code: IUMS. 101568). Then the patients were recruited from those who referred to Rasoul-e-Akhram Hospital in Tehran. Sample size was determined based on p = 0.4, p2 = 0.15, = 1.96, = 0.84 1 z1 - α/2 z1 - β and d = 0.25. Thus, 155 patients who were willing to participate in this study and had the inclusion criteria were randomly selected. A simple randomized sampling procedure was carried out on the basis of study criteria using the “Random Allocation Software” program, but 148 patients were included in the study. The inclusion criteria were ages 18 - 60, ability to swallow capsules, platelet counts above 100,000, no obesity and hepatitis, no pregnancy, the lack of epilepsy, diabetes, and kidney diseases and cancer, not using antiemetic drugs, no long-term treatment with corticosteroids, and no history of allergy to Ginger or Ondansetron. All eligible patients were randomly divided into three groups, by sealed envelopes, as (A) Ginger, (B) Ondansetron, and (C) Placebo capsule. The sample recruitment process is shown in
Figure 1. The patients, those administering the drug, and those registering the signs and symptoms of the patients were unaware of the medicine used for each group.
The sampling was conducted after introducing the method and written informed consent was obtained from all subjects participating in the study. Ginger capsule (1,000 mg), Ondansetron capsule (16 mg), and placebo capsule were prepared in a pharmacological laboratory of Iran University of Medical Sciences with the same shape. In the next step, medications were randomly assigned to the research unit. The patients in three groups received capsules with 30 ml of water one hour before surgery.
The anesthesia technique, type of anesthetic drug, and duration of anesthesia were the same in all participants. The medication of anesthesia induction included midazolam 2 mg, fentanyl 2 μg/kg, thiopental 5 mg/kg, atracurium 0.5 mg/kg. Also, 50% oxygen and 50% N2O were used for the maintenance of anesthesia. Medications that could cause nausea and vomiting, such as morphine, were not used in the study. Nausea was recorded on a 10 cm visual analogue scale (VAS), which ranged from 0 to 10, scores 0, 1 - 3, 4 - 6, 7 - 9, and 10 that were allocated to no nausea, mild, moderate, severe, and very severe nausea, respectively (
19). The number of vomiting episodes was recorded (
20). Antiemetic drugs (Ondansetron 2 mg IV PRN) were prescribed for those patients who had more than two vomiting episodes.
In the researchers-made checklist, the patient’s demographic information included age, gender, weight, smoking, surgery duration, systolic and diastolic pressure, heart rate, respiratory rate, temperature, anesthetic and sedation drugs used, duration of the anesthesia and onset of recovery, the frequency of vomiting, the severity of nausea recorded at different times (immediately after recovery, 1, 2 and 4 hours after recovery from anesthesia). In addition, possible complications such as abdominal pain, heartburn, shortness of breath, diarrhea, and insomnia were asked and recorded. A checklist and a standard tool (VAN) (
19) were used by a researcher to evaluate the severity of nausea and vomiting among the participants. The participants, researchers, and the statistical analyzer were unaware of which drugs were received. Finally, the quantitative variables were compared using paired
t-test or one-way ANOVA followed by Tukey test for pairwise comparisons. The comparison of qualitative variables was performed using contingency tables, chi-square, or Fisher’s exact test. A P value of ≤ 0.05 was considered statistically significant.